Law firm Kahn Swick & Foti is investigating the proposed merger between Predictive Oncology and Renovaro, questioning whether the transaction adequately values the company.

The White House is encouraging AI adoption in healthcare through regulatory sandboxes, with several tech and biotech companies advancing AI-powered healthcare solutions focused on diagnostics, drug development, and workflow optimization.

Renovaro Inc. has received a ruling to expedite a trial in 2025 for a lawsuit it filed against Predictive Oncology Inc., seeking to enforce a binding merger agreement executed on January 1, 2025. Renovaro alleges that Predictive Oncology breached the agreement's exclusivity and good faith negotiation provisions.

Renovaro Inc. has filed a lawsuit against Predictive Oncology Inc. to enforce a binding merger agreement, alleging that Predictive Oncology breached the agreement's exclusivity and good faith negotiation provisions.

Predictive Oncology reported a loss of $10.8 million on $1.6 million in revenue for 2024. The company announced an agreement to merge with Renovaro, Inc. and the receipt of financing to integrate their AI/ML platform and laboratory capabilities.